Compare Mesoblast Limited (MESO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 65.4× Mesoblast Limited's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| MESO | SGOV | |
|---|---|---|
Market Cap | $1.75B | $114.40B |
Volume | 239,027 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $20.96 | $100.72 |
52-Week Low | $13.19 | $100.28 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill holdings. The ETF shows bearish technical signals with 17 sell indicators versus 4 buy signals, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026. The fund continues its consistent dividend payments with recent distributions of $0.30-$0.31 per share.
SGOV provides exposure to ultra-short-term Treasury securities, offering stability amid bond market volatility. The ETF faces headwinds from rising interest rates but benefits from flight-to-quality flows. Key risks include interest rate sensitivity and potential yield compression if Fed policy shifts dovishly. Current technical weakness may present entry opportunities for income-focused investors seeking capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
